B of A Securities Reiterates Rating on Avalo Therapeutics, Inc. $AVTX
Key Points
- B of A Securities now rates Avalo Therapeutics, Inc. ($AVTX) "buy" with a $35.00 target.
- The Street's average $AVTX price target is $46.18 (Strong Buy).
- $AVTX last traded around $13.68.
B of A Securities reiterated its rating on Avalo Therapeutics, Inc. ($AVTX) to a "buy" rating, with a price target of $35.00 in a recent research note.
Avalo Therapeutics, Inc. ($AVTX) Stock
Avalo Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.